ClinicalTrials.gg

Program

HSK7653

A development code. Also written as “HSK7653 10 mg”, “HSK7653 10 mg Q2W” and “HSK7653 25 mg Q2W”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Glucose Intolerance · Renal Insufficiency, led by Haisco Pharmaceutical Group.

Furthest: phase 3, since Sep 14, 202010 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haisco Pharmaceutical Group100 open or runningphase 3since Sep 14, 2020Aug 25, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 25, 2020First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT04540016 · 6 enrolled · China
  2. Sep 14, 20202 phase 3 studies in Diabetes Mellitus, Type 2NCT04564872, NCT04556851
  3. Jan 21, 2021Phase 2 study in Glucose IntoleranceNCT04727580 · 99 enrolled · China
  4. Aug 9, 2022Phase 1 study in Renal InsufficiencyNCT05497297 · 42 enrolled · China
  5. Jan 11, 2023Phase 1 study in HealthyNCT06003088 · 48 enrolled · China
  6. Aug 1, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05983289 · 62 enrolled · China
  7. Sep 23, 2023Phase 2 study in Diabetes Mellitus, Type 2NCT06059326 · 48 enrolled · China
  8. Sep 24, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT06084156 · 22 enrolled · China
  9. Nov 21, 2024Phase 2 study in Diabetes Mellitus, Type 2NCT06703268 · 64 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06703268Diabetes Mellitus, Type 2 · China2CompletedOct 5, 202464
NCT06084156Diabetes Mellitus, Type 2 · China1CompletedDec 9, 201922
NCT06059326Diabetes Mellitus, Type 2 · China2CompletedNov 5, 201948
NCT05983289Diabetes Mellitus, Type 2 · China1CompletedJul 3, 201962
NCT06003088Healthy · China1CompletedAug 12, 202248
NCT05497297Renal Insufficiency · China1CompletedOct 23, 202242
NCT04727580Glucose Intolerance · China2CompletedJun 12, 202299
NCT04564872Diabetes Mellitus, Type 2 · China3CompletedJan 21, 2022465
NCT04556851Diabetes Mellitus, Type 2 · China3CompletedJan 10, 2022476
NCT04540016Diabetes Mellitus, Type 2 · China1CompletedJan 14, 20216

How it is read

Names in the registry

  • “HSK7653 10 mg”, 2 entries
  • “HSK7653”, 2 entries
  • “HSK7653 10 mg Q2W”, 2 entries
  • “HSK7653 25 mg Q2W”, 2 entries
  • “HSK7653 10mg Q2W”, 1 entry

Codes read as this program: HSK7653.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.